Athos Therapeutics
Athos Therapeutics is a clinical-stage biotech developing AI-based precision small molecule therapeutics for autoimmune diseases and cancer, with its AthosOmics.AI platform producing lead candidate ATH-063 in Phase 2 trials for ulcerative colitis.
- Company typePrivate
- Founded2019
- HeadquartersTorrance, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Athos Therapeutics does
Athos Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in Torrance, California, that develops AI-based precision small molecule therapeutics for patients with inflammatory bowel disease, other autoimmune conditions, and cancer. Its core technology is the proprietary AthosOmics.AI platform, which ingests multi-omics data (proteomics, genomics, metabolomics) to identify biomarkers and generate drug candidates; the lead asset ATH-063 has advanced to Phase 2 clinical trials for ulcerative colitis. Athos trains its in-house AI models on cloud GPU infrastructure (Vultr running on Dell Nvidia HGX H100 servers), reporting a 10x acceleration in model training after migrating from on-premises hardware. The company operates with 11–50 employees under Co-Founder and CEO Dr. Dimitrios Iliopoulos (formerly of Harvard Medical School and the UCLA Center for Systems Biomedicine) and Co-Founder and Chief Medical Officer Allan J. Pantuck.
Athos is pre-revenue and follows a traditional clinical-stage biotech commercial model: it advances candidates through regulatory phases with the intent to monetize via out-licensing, partnership deals, or eventual commercialization with a larger pharmaceutical counterparty upon approval. Additional revenue optionality comes from platform-based services — demonstrated by a 2025 partnership with Xeptiva Therapeutics applying AthosOmics.AI to biomarker discovery for a canine osteoarthritis vaccine. Cumulative disclosed funding totals approximately $54.25 million across a 2020 round ($4.25M), a 2021 Series A ($15M), and a 2024 Series B targeting $35M, with roughly $10M of the Series B earmarked for the lead inflammation asset.
Athos Therapeutics firmographics
Firmographics- Name
- Athos Therapeutics
- Legal name
- Athos Therapeutics Inc.
- Website
- https://athostx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Athos Therapeutics is a clinical-stage biotech developing AI-based precision small molecule therapeutics for autoimmune diseases and cancer, with its AthosOmics.AI platform producing lead candidate ATH-063 in Phase 2 trials for ulcerative colitis.
- Ownership category
- akta.pro rank
Athos Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
Keywords
Where Athos Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Torrance
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Athos Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage biotech company. Revenue will be generated through eventual drug commercialization or licensing/partnership deals with larger pharmaceutical companies upon successful clinical development and regulatory approval of AI-developed precision small molecule therapeutics.
- Platform Licensing and Partnership Services: The company provides AI-driven omics analysis services to partners through the AthosOmics.AI platform, as demonstrated by the partnership with Xeptiva Therapeutics for biomarker discovery in veterinary medicine.
Go-to-market motion1 record
Marketing channels1 record
Athos Therapeutics product offering
Product offeringCore offering
Athos Therapeutics is a clinical-stage biotechnology company that uses its proprietary AthosOmics.AI platform to analyze omics data (proteomics, genomics, metabolomics) to discover biomarkers and develop precision small molecule therapeutics targeting autoimmune diseases and cancer. Its lead drug candidate, ATH-063, is currently in Phase 2 clinical trials for ulcerative colitis, with additional candidates in development for cancer and other inflammatory conditions. The company also provides AI-driven omics analysis services to partners for biomarker discovery applications.
Product overview
Athos Therapeutics is a clinical-stage biotechnology company developing AI-powered precision medicine. Its core offering is the AthosOmics.AI platform, an AI-driven drug development system that analyzes omics data to discover biomarkers and produce precision small molecule therapeutics. The platform has generated drug candidates including ATH-063 (in Phase 2 for ulcerative colitis) targeting autoimmune diseases and cancer. The company operates a cloud-based AI infrastructure (Vultr GPU-as-a-service) for training its proprietary AI models.
Differentiator
Problem solved
Functional benefit
Products and services
- AthosOmics.AI AI-driven drug development platform that analyzes omics data (proteomics, genomics, metabolomics) to identify biomarkers and produce precision small molecule therapeutics targeting autoimmune diseases and cancer. The platform has produced drug candidates including ATH-063 currently in Phase 2 clinical trials for ulcerative colitis. Also deployed for partner biomarker discovery engagements such as the Xeptiva Therapeutics veterinary medicine collaboration.
- ATH-063 Lead precision small molecule drug candidate produced by the AthosOmics.AI platform, currently in Phase 2 clinical trials for ulcerative colitis. It targets inflammation associated with autoimmune disease and represents Athos Therapeutics' most advanced clinical asset.
Quantifiable outcome
- 10x faster model training compared to on-premises infrastructure
- +1 more outcomes
Companies that use Athos Therapeutics
Customer profileSegments4 records
Ideal customer profiles2 records
Athos Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature3 records
Athos Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Cosmos Health Inc.coreDr. Dimitrios Iliopoulos, Co-Founder and CEO of Athos Therapeutics, was appointed to Cosmos Health's Advisory Board to support biotechnology initiatives focused on AI-driven drug discovery and clinical-stage therapeutic development. This appointment strengthens Cosmos Health's R&D initiatives and supports expansion into oncology, autoimmune diseases, and other high-value therapeutic areas.
- Xeptiva TherapeuticscoreAthos Therapeutics and Xeptiva Therapeutics announced a partnership to utilize the AthosOmics.AI platform for analyzing omics data from clinical trial plasma samples of canines to identify biomarkers related to Xeptiva's therapeutic vaccine for osteoarthritis chronic pain. This collaboration aims to support veterinary precision medicine development using AI-driven omics analysis.
Scale indicators5 records
Expansion highlights4 records
Athos Therapeutics competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Clinical-stage AI-native drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Direct comparable to Athos in using proprietary multi-omics and AI platform to generate precision small molecule candidates, with broader pipeline and significantly larger capital base.
- Exscientia: AI-driven precision medicine company developing small molecule therapeutics through partnerships with major pharma. Directly comparable to Athos in applying AI to drug discovery, with multiple partnered programs and clinical-stage assets.
- Insitro: AI-driven drug discovery platform combining machine learning, high-throughput biology, and human cohort data to discover therapeutics. Comparable to Athos in applying AI/ML to multi-omics data for precision drug development, with significant partnerships with Bristol Myers Squibb and others.
- BenevolentAI: Clinical-stage AI drug discovery company leveraging multi-omics data and machine learning for drug target identification. Directly comparable to Athos's AI-driven omics analysis approach with clinical assets in autoimmune/inflammatory diseases.
- Schrödinger: Computational drug discovery platform combining physics-based simulation with machine learning for small molecule design. Comparable to Athos in using computational methods to accelerate precision small molecule development with multiple partnered and internal programs.
- Atomwise: AI-driven small molecule drug design company using deep learning for hit identification and lead optimization. Directly comparable to Athos in applying AI to small molecule precision medicine, with multiple pharma partnerships.
- Generate Biomedicines: Generative AI biology company creating novel therapeutics from programmable molecular design. Comparable to Athos in using AI/ML for novel drug candidate generation across multiple therapeutic areas, with strong venture backing.
Emerging players
- AbCellera: AI-powered antibody discovery platform combining microfluidics, genomics, and machine learning. Partially comparable to Athos as an AI-driven biologics discovery platform, though focused on antibodies rather than small molecules.
- Iterative Health: AI-driven precision medicine company focused on gastroenterology and inflammatory bowel disease. Directly comparable to Athos's lead ATH-063 indication (ulcerative colitis), with AI applied to IBD clinical research and drug development.
Broad incumbents
- Roivant Sciences: Clinical-stage precision medicine company with multiple therapeutic subsidiaries developing small molecules and biologics across autoimmune and inflammatory diseases. Comparable to Athos in precision medicine approach with broader pipeline and significantly more capital.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Athos Therapeutics social profiles
Digital presenceAthos Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Athos Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Athos Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Athos Therapeutics M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Athos Therapeutics
What does Athos Therapeutics do?
Athos Therapeutics is a clinical-stage biotechnology company that uses its proprietary AthosOmics.AI platform to analyze omics data (proteomics, genomics, metabolomics) to discover biomarkers and develop precision small molecule therapeutics targeting autoimmune diseases and cancer. Its lead drug candidate, ATH-063, is currently in Phase 2 clinical trials for ulcerative colitis, with additional candidates in development for cancer and other inflammatory conditions. The company also provides AI-driven omics analysis services to partners for biomarker discovery applications.
Is Athos Therapeutics a public or private company?
Athos Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Athos Therapeutics founded?
Athos Therapeutics was founded in 2019. It employs 11 to 50 people.
Where is Athos Therapeutics based?
Athos Therapeutics is headquartered in Torrance, United States, in the North America region.
How does Athos Therapeutics make money?
Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are platform Licensing and Partnership Services.
Who are Athos Therapeutics's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Exscientia, Insitro, BenevolentAI, Schrödinger, Atomwise and Generate Biomedicines. Emerging players are AbCellera and Iterative Health. Roivant Sciences is listed as a broad incumbent.
Does Athos Therapeutics have an API?
No public API is recorded for Athos Therapeutics.
What industry is Athos Therapeutics in?
Athos Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.